11. A pharmaceutical composition according to any one of the claims 1-10, in the form of a cream, liquid, lotion, gel, spray, foam or ointment.

12. A patch, stick, spray dispenser, tube, or pen containing a pharmaceutical composition according to any one of the claims 1-11.

13. The compound 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt for use in the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject by topical administration of a therapeutically effective dose thereof to the skin or mucous membrane of the mammal subject.

14. The compound according to claim 13, wherein an additional pharmaceutically active ingredient, is topically administered, in sequence or in combination with B-220 or its pharmaceutically acceptable salt.

15. The compound according to claim 14, wherein the additional pharmaceutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anaesthetic agents, antiphlogistic agents and antiinflammatory agents.

16. Use of a pharmaceutical composition according to any of claims 1-8 in the manufacture of a medicament for prophylaxis and/or treatment of a herpes virus infection in a mammal subject.

17. Use of a pharmaceutical composition according to any one of the claims 1-9 in the manufacture of a medicament for dermal or mucosal treatment.

18. Use of the compound 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt in the manufacture of a medicament for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject, wherein a therapeutically effective dose of the medicament is to be topically administered to the skin or mucous membrane of the mammal subject.

19. The use according to claim 18, wherein an additional pharmaceutically active ingredient is to be topically administered, in sequence or in combination with B-220 or its pharmaceutically acceptable salt.

20. The use according to claim 19, wherein the additional pharmaceutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anaesthetic agents, antiphlogistic agents and antiinflammatory agents.